

Interim Financial Statements
Half Year Ended
June 30, 2013



BEXIMCO PHARMACEUTICALS LTD.

Beximco Pharmaceuticals Limited
Statement of the Managing Director

Dear Shareholders,

We are pleased to present the un-audited interim financial results for the half year ended June 30, 2013 in compliance with Rule 13 of the Securities and Exchange Commission Rules 1987.

We continued to make progress in the first half of 2013 with reported results largely in line with our expectations. Despite the unstable political environment prevailing in the country throughout this half, we managed to achieve a sales growth higher than the industry average. The Company achieved net sales revenue of Tk. 4,966.4 million, up 14.3% over the corresponding period in 2012. This furnished pre-tax profits of Tk. 955.6 million compared to Tk. 847.7 million earned during the same period in the previous year.

Our export sales registered an excellent 70.7% growth to reach Tk. 331.4 million. In the first quarter of this year, we entered into the European market through commencement of export to Germany and Austria. This is a significant milestone, not only for the Company alone, but for the entire Bangladesh Pharmaceutical Industry. This is for the first time that a Bangladeshi company has succeeded in exporting its own pharmaceutical formulations to Europe. Additionally, in this half, we have obtained marketing authorization for a product in Australia.

We continued to make progress in our domestic markets with the launch of eighteen new products; five of them being introduced in the country for the first time. We have also successfully registered 23 products in seven overseas markets during this six-month period.

At this halfway point in the year, we are pleased with our progress achieved to date and notwithstanding a further worsening of the overall political environment, we remain hopeful of achieving our year-end targets.

We look forward to your continued support.

Nazmul Hassan

Nazmul Hassan
Managing Director

Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at June 30, 2013

Taka'000

ASSETS	Notes	As at June 30, 2013	As at December 31, 2012
Non-Current Assets		16,331,183	16,392,388
Property, Plant and Equipment- Carrying Value	3	16,126,145	16,201,858
Intangible Assets		201,587	187,079
Investment		3,451	3,451
Current Assets		8,629,567	8,197,422
Inventories	4	2,567,022	2,433,988
Spares & Supplies		413,166	396,176
Accounts Receivable		1,210,546	1,162,405
Loans, Advances and Deposits	5	1,042,813	965,276
Short Term Investment		2,797,418	2,686,598
Cash and Cash Equivalents	6	598,602	552,979
TOTAL ASSETS		<u>24,960,750</u>	<u>24,589,810</u>
EQUITY AND LIABILITIES			
Shareholders' Equity		19,025,445	18,408,162
Issued Share Capital		3,503,349	3,046,390
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,356,189	1,406,528
Retained Earnings		6,911,844	6,701,181
Non-Current Liabilities		3,204,839	3,116,704
Long Term Borrowings-Net off Current Maturity (Secured)	7 A	1,284,162	1,469,622
Liability for Gratuity & WPPF		638,401	499,623
Deferred Tax Liability		1,282,276	1,147,459
Current Liabilities and Provisions		2,730,466	3,064,944
Short Term Borrowings		1,166,804	1,526,450
Long Term Borrowings-Current Maturity	7 B	767,009	664,713
Creditors and Other Payables		374,719	470,097
Accrued Expenses		59,170	128,599
Dividend Payable		999	1,021
Income Tax Payable		361,765	274,064
TOTAL EQUITY AND LIABILITIES		<u>24,960,750</u>	<u>24,589,810</u>

Nazmul Hassan

Nazmul Hassan
Managing Director

Ali Nawaz

Ali Nawaz
Chief Financial Officer

Beximco Pharmaceuticals Limited
Statement of Comprehensive Income (Un-audited)
For the Half Year Ended June 30, 2013

Taka'000

	Notes	Half-Year ended June 30, 2013	Half-Year ended June 30, 2012	2nd Quarter (April - June) 2013	2nd Quarter (April - June) 2012
Net Sales Revenue		4,966,358	4,346,354	2,703,345	2,123,984
Cost of Goods Sold	8	(2,728,766)	(2,367,543)	(1,464,384)	(1,151,431)
Gross Profit		2,237,592	1,978,811	1,238,961	972,553
Operating Expenses :		(1,189,495)	(966,300)	(619,698)	(473,270)
Administrative Expenses	9	(196,164)	(150,882)	(104,614)	(77,265)
Selling, Marketing and Distribution Expenses	10	(993,331)	(815,418)	(515,084)	(396,005)
Profit from Operations		1,048,097	1,012,511	619,263	499,283
Other Income		247,518	207,323	125,075	104,804
Finance Cost		(292,218)	(329,725)	(143,573)	(169,469)
Profit Before Contribution to WPP & Welfare Funds		1,003,397	890,109	600,765	434,618
Contribution to WPP & Welfare Funds		(47,781)	(42,386)	(28,608)	(20,696)
Profit Before Tax		955,616	847,723	572,157	413,922
Income Tax Expenses		(297,112)	(234,318)	(196,580)	(107,829)
Profit After Tax		658,504	613,405	375,577	306,093
Other Comprehensive Income		-	-	-	-
Total Comprehensive Income		658,504	613,405	375,577	306,093
Earnings Per Share (EPS) / Restated EPS	Tk.	1.88	1.75	1.07	0.87
Number of Shares used to compute EPS (Note 11)		350,334,907	350,334,907	350,334,907	350,334,907

Nazmul Hassan

Nazmul Hassan
Managing Director

Ali Nawaz

Ali Nawaz
Chief Financial Officer

Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the Period ended June 30, 2013

Taka'000

Half Year ended June 30, 2013								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Retained Earnings	Total	
Balance as on January 01, 2013	3,046,390	5,269,475	1,689,637	294,951	1,406,528	6,701,181	18,408,162	
Total Comprehensive Income	-	-	-	-	-	658,504	658,504	
Stock Dividend for 2012	456,959	-	-	-	-	(456,959)	-	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(9,118)	9,118	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(41,221)	-	(41,221)	
As on June 30, 2013	3,503,349	5,269,475	1,689,637	294,951	1,356,189	6,911,844	19,025,445	
Number of Shares on June 30, 2013							350,334,907	
Net Asset Value (NAV) Per Share						Tk.	54.31	

Half Year ended June 30, 2012								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Retained Earnings	Total	
Balance as on January 01, 2012	2,517,678	5,269,475	1,689,637	294,951	1,466,603	5,889,785	17,128,129	
Total Comprehensive Income	-	-	-	-	-	613,405	613,405	
Stock Dividend for 2011	528,712	-	-	-	-	(528,712)	-	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(10,360)	10,360	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(46,577)	-	(46,577)	
As on June 30, 2012	3,046,390	5,269,475	1,689,637	294,951	1,409,666	5,984,838	17,694,957	
Number of Shares on June 30, 2012							304,639,050	
Net Asset Value (NAV) Per Share						Tk.	58.08	

Nazmul Hassan

Nazmul Hassan
 Managing Director

Ali Nawaz

Ali Nawaz
 Chief Financial Officer

Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the Half-year ended June 30, 2013

Taka'000

	Half-Year ended June 30, 2013	Half-Year ended June 30, 2012
--	-------------------------------------	-------------------------------------

Cash Flows from Operating Activities :

Receipts from Customers and Others	4,917,071	4,300,864
Payments to Suppliers and Employees	(3,924,666)	(3,083,742)
Cash Generated from Operations	992,405	1,217,122
Interest Paid	(292,218)	(329,725)
Interest Received	248,664	204,036
Income Tax Paid	(115,816)	(88,647)
Net Cash Generated from Operating Activities	833,035	1,002,786

Cash Flows from Investing Activities :

Acquisition of Property, Plant and Equipment	(212,249)	(704,325)
Intangible Assets	(21,571)	(21,207)
Disposal of Property, Plant and Equipment	60	4,480
Short Term Investment	(110,820)	(353,195)
Net Cash Used in Investing Activities	(344,580)	(1,074,247)

Cash Flows from Financing Activities :

Net Increase / (Decrease) in Long Term Borrowings	(83,164)	(54,862)
Net Increase / (Decrease) in Short Term Borrowings	(359,646)	119,294
Ordinary Share Dividend	(22)	(132)
Net Cash Generated from Financing Activities	(442,832)	64,300
Increase / (Decrease) in Cash and Cash Equivalents	45,623	(7,161)
Cash and Cash Equivalents at Beginning of Period	552,979	518,768
Cash and Cash Equivalents at End of Period	598,602	511,607
Net Operating Cash Flow Per Share	Tk. 2.38	3.29

Number of Shares used to compute Net Operating Cash Flow Per Share	350,334,907	304,639,050
--	-------------	-------------

Nazmul Hassan

Nazmul Hassan
 Managing Director

Ali Nawaz

Ali Nawaz
 Chief Financial Officer

Beximco Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-audited)
For the Period ended June 30, 2013

1. Reporting Entity

Beximco Pharmaceuticals Limited (BPL/the Company) is a public company incorporated in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company is listed on Dhaka and Chittagong Stock Exchanges of Bangladesh and AIM of London Stock Exchange. The company is engaged in manufacturing and marketing of Pharmaceuticals Finished Formulation Products, Active Pharmaceutical Ingredients (APIs) and life saving Intravenous Fluids which it sells in the local as well as international markets. The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The Industrial units are located at Tongi and Kaliakoir of Gazipur District - vicinities close to the capital city Dhaka.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the year ended December 31, 2012 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

	As at June 30, 2013	As at December 31, 2012
3. Property, Plant & Equipment		
Cost / Revaluation		
Land	3,302,882	3,302,102
Building and Other Constructions	6,340,926	6,333,171
Plant & Machinery	7,454,110	7,393,576
Furniture & Fixture	164,502	157,600
Transport & Vehicle	459,542	458,377
Office Equipment	344,035	329,522
	18,065,997	17,974,348
Accumulated Depreciation	(4,402,592)	(4,114,781)
	13,663,405	13,859,567
Capital Work in Progress	2,462,740	2,342,291
Carrying Value	<u>16,126,145</u>	<u>16,201,858</u>

Taka'000

	As at June 30, 2013	As at December 31, 2012
4. Inventories		
Finished Goods	604,163	629,829
Raw and Packing Material (Including Work in Process and Transit)	1,892,928	1,737,244
Sample & Others	69,931	66,915
	<u>2,567,022</u>	<u>2,433,988</u>
5. Loans, Advances and Deposits		
Clearing & Forwarding	31,635	19,351
VAT	207,474	215,793
Security Deposit and Earnest Money	20,513	23,151
Capital Expenditure / Project Expenses	54,725	54,725
	119,150	63,699
Advance against Salary	60,269	64,266
Motor Cycle	118,206	132,315
Raw & Packing Material	350,813	330,283
Overseas Liaison Office	19,444	17,420
Others	60,584	44,273
	<u>1,042,813</u>	<u>965,276</u>
6. Cash and Cash Equivalents		
(a) Cash In Hand (Including Imprest Cash)	2,735	2,540
(b) Cash at Bank:		
i) Current & FC Account	106,986	85,035
ii) FDR Account	488,881	465,404
	<u>598,602</u>	<u>552,979</u>
7. Long Term Borrowings		
A. Net off Current Maturity (Secured)		
Project Loan	1,197,123	1,336,417
Obligation Under Finance leases	87,039	133,205
	<u>1,284,162</u>	<u>1,469,622</u>
B. Current Maturity		
Project Loan	674,677	568,589
Interest and PAD Block	-	3,792
Obligation Under Finance leases	92,332	92,332
	<u>767,009</u>	<u>664,713</u>

Taka'000


	Half Year ended June 30, 2013	Half Year ended June 30, 2012
8. Cost of Goods Sold		
Materials	1,987,741	1,745,854
Factory Overhead	480,474	361,255
Depreciation	260,551	260,434
	<u>2,728,766</u>	<u>2,367,543</u>
9. Administrative Expenses		
Salary & Allowances	81,937	68,214
Repairs & Maintenance	15,142	10,267
Travelling & Conveyance	8,546	8,425
AGM, Company Secretarial Expenses and Regulatory Fees	25,295	24,409
Depreciation	10,077	10,072
Other Expenses	55,167	29,495
	<u>196,164</u>	<u>150,882</u>
10. Selling, Marketing and Distribution Expenses		
Salary & Allowances	316,063	254,680
Travelling & Conveyance	132,043	112,038
Market Research & New Products	19,036	18,624
Sample, Literature & Promotional Expenses	288,885	235,531
Delivery Expense	146,901	116,679
Depreciation and Amortization	24,338	23,380
Other Expenses	66,065	54,486
	<u>993,331</u>	<u>815,418</u>

11. Dividend for 2012

The Shareholders of the company has approved 15% stock dividend for the year 2012 in the annual general meeting held on June 29, 2013. The company consistently follows the policy of recognising proposed dividend after its approval by the shareholders in the annual general meeting. Hence, the dividend for 2012 has been accounted for in this interim financial statements. EPS has been computed taking into account the additional number of shares issued.



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer

Corporate Information

Operational Headquarters

19 Dhanmondi R/A, Road # 7
Dhaka 1205, Bangladesh
Phone : +880-2-8619151, +880-2-8619091
Fax : +880-2-8613888
E-mail : info@bpl.net
Website : www.beximcopharma.com

Corporate Headquarters

17 Dhanmondi R/A, Road # 2
Dhaka 1205, Bangladesh
Phone : +880-2-8611891
Fax : +880-2-8613470
E-mail : beximchq@bol-online.com

Factory

Tongi Unit
126 Kathaldia, Tongi, Gazipur
Bangladesh

Kaliakoir Unit
Plot No. 1070/1083, Mouchak
Kaliakoir, Gazipur
Bangladesh

Stock Exchange Listing

Dhaka Stock Exchange Ltd.
Chittagong Stock Exchange Ltd.
AIM of London Stock Exchange plc (GDRs)

Public Relations

IMPACT PR
Apartment # A-1, House # 17,
Road # 4, Gulshan-1,
Dhaka-1212, Bangladesh

FTI Consulting Group Limited
Holborn Gate, 26 Southampton Buildings
London WC2A 1PB, UK

Legal Advisor

Rafique-ul Huq
Barrister-at-Law
47/1 Purana Paltan
Dhaka-1000, Bangladesh

Auditors

M. J. Abedin & Co.
Chartered Accountants
National Plaza (3rd Floor)
109, Bir Uttam C. R. Datta Road
Dhaka-1205, Bangladesh

Banker

Janata Bank Ltd.
Local office
1 Dilkusha C/A
Dhaka-1000, Bangladesh

For GDRs

Nominated Advisor

Libertas Capital Corporate Finance Limited
21 Wilson Street
London EC2M 2SN

Broker

Daniel Stewart and Company PLC
Becket House
36, Old Jewry
London EC 2R 8DD

Custodian

HSBC
Anchor Tower, 1/1-B, Sonargaon Road
Dhaka-1205, Bangladesh

Depository Bank

The Bank of New York Mellon
101 Barclay Street
New York, NY 10286



BEXIMCO PHARMACEUTICALS LTD.



Winner



Therapeutic Goods Administration



Certified

